A randomised trial to compare dolutegravir plus boosted darunavir versus recommended standard of care antiretroviral regimens in people with HIV-1, whose first-line non-nucleoside reverse transcriptase inhibitor therapy has failed: Final 96-week results of the D2EFT study

Journal:

Clinical Infectious Diseases

Published:

2025-06-27

DOI:

10.1093/cid/ciaf346

Affiliations:

25

Authors:

26

Go to article

Institutions	Authors	Share
University of New South Wales (UNSW Sydney), Australia	8.000000	0.31
University of Zimbabwe (UZ), Zimbabwe	1.000000	0.04
Institute of Human Virology, Nigeria (IHVN), Nigeria	1.000000	0.04
Desmond Tutu Health Foundation (DTHF), South Africa	1.000000	0.04
Coordinación en Investigación Clínica Académica en Latinoamérica (CICAL), Argentina	1.000000	0.04
University of Malaya (UM), Malaysia	1.000000	0.04
Indonesia Research Partnership on Infectious Diseases (INA-RESPOND), Indonesia	1.000000	0.04
Mali-University Clinical Research Center (UCRC), Mali	1.000000	0.04
Donka Hospital, Guinea	1.000000	0.04
Hospital Civil de Guadalajara, Mexico	1.000000	0.04
CAICI Institute, Argentina	1.000000	0.04
Oswaldo Cruz Foundation (FIOCRUZ), Brazil	1.000000	0.04
Universitas Airlangga Hospital (RSUA), Indonesia	1.000000	0.04
ViiV Healthcare Australia, Australia	1.000000	0.04
Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), India	0.500000	0.02
Voluntary Health Services (VHS), India	0.500000	0.02
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thailand	0.500000	0.02
Chulalongkorn University (CU), Thailand	0.500000	0.02
Cipto Mangunkusumo General Hospital, Indonesia	0.500000	0.02
University of Indonesia (UI), Indonesia	0.500000	0.02
Gadjah Mada University (UGM), Indonesia	0.500000	0.02
Dr. Sardjito Hospital, Indonesia	0.500000	0.02
Universitas Hasanuddin (UNHAS), Indonesia	0.500000	0.02
Dr.Wahidin Sudirohusodo Hospital, Indonesia	0.500000	0.02

Interested in Clinical Sciences?